ライフサイエンスコーパス: annexin I

1 apoptotic cells indicates a requirement for annexin I.

2 pendent manner were identified as S100A8 and annexin I.

3 localized to a carboxyl-terminal fragment of annexin I.

4 han that of annexin V but lower than that of annexin I.

5 ns may play critical roles in the folding of annexin I.

6 ential for Ca2+-dependent vesicle binding of annexin I.

7 to a site within the first 12 amino acids of annexin I.

8 nce in lung cancer sera of autoantibodies to annexin I, 14-3-3 theta, and a novel lung cancer antigen

9 Annexin is a noninvasive method to identify plaque apopt

10 e nucleotide-binding protein (beta-subunit), annexin I, a gene encoding a kinesin-like protein, and T

11 ific polyclonal antibodies identified p37 as annexin I, a member of a family of Ca(2+)-dependent phos

12 age of 100% of annexins V and VI, but 41% of annexin I and 12% of annexin III are retained.

13 Using these methods, it was shown that both annexin I and annexin VII bind to bovine apoA-I in a Ca2

14 An intact N terminus of annexin I and heteromeric assembly of S100A8 with S100A9

15 We also sequenced peptides derived from annexin I and plasminogen activator inhibitor 2, two put

16 In cellular extracts, endogenous annexin I and the 10-kDa protein associated in a reversi

17 that a chimera composed of residues 24-35 of annexin I and the core of annexin V has vesicle aggregat

18 mportance of domain II in vesicle binding of annexin I and the involvement of domains III and IV in v

19 and is highly specific to AIIt because other annexins (I and II monomer, III, IV, V, and VI) were una

20 nclude that an immune response manifested by annexins I and II autoantibodies occurs commonly in lung

21 uorescence microscopy revealed that retained annexins I and III are associated with granule membranes

22 Addition of soluble annexins I and III to permeabilized cells increased Ca2+

23 s of highly sensitive and precise assays for annexins I and V, utilizing turbidometric analysis of ph

24 against proteins identified as glycosylated annexins I and/or II.

25 t cytoplasmic lipocortin 1 (LC1, also called annexin I)', and the activity profile of this protein su

26 CA1), SCC antigen 2 (SCCA2), S100A8, S100A9, Annexin I, and Annexin II] in the squamous NHTBE cells w

27 100 proteins to short N-terminal peptides of annexin I (AnI) and annexin II (AnII) was investigated u

28 The identities of PKC, annexin I, annexin IV, annexin VI, and annexin VII were

29 in solution with binding detected using anti-annexin I antiserum.

30 Two annexin I (anxI) genes, called cp35 and cp37, are expres

31 anism of chronic inflammatory diseases where annexin I autoantibodies have been described.

32 id monolayer was 31 +/- 2 A, indicating that annexin I binds membranes as a protein monomer or monola

33 Annexin bridging is vectorial, because annexin is bound to PS molecules on targets but not on m

34 t apoptotic thymocytes, were stained by anti-annexin I but not II.

35 eral proteins were eluted from a recombinant annexin I column in the presence of 2 mM EGTA, including

36 f the crystal structure of a truncated human annexin I containing all four domains, indicating that t

37 rally aggregated monolayer of membrane-bound annexin I directly interacts with a secondary membrane v

38 duce and stabilize an active conformation of annexin I for vesicle aggregation.

39 ansferase fused to amino acids 2-47 of human annexin I (GST-AINT; AINT = annexin I N-terminal).

40 e structure of an isolated domain 1 of human annexin I has been determined by NMR spectroscopy.

41 It has been proposed that annexin I has two separate interaction sites that are in

42 hat cAMP and AMP (but not cGMP) may regulate annexin I histidine phosphorylation.

43 ur annexins containing KFERQ-like sequences, annexins I, II, IV, and VI, are enriched in lysosomes wi

44 These two inclusions were not labeled for annexins I, II, IV, and VI; alpha-adaptin; clathrin heav

45 Some annexins, including annexins I, II, IV, and VII, can promote membrane aggreg

46 sized that the reduced or lost expression of annexin I/II might promote certain aggressive phenotypes

47 t effect on liposome aggregation mediated by annexins I, III or IV.

48 We propose a role for annexin I in an intracellular signaling system involving

49 also revealed reduced or lost expression of annexin I in prostate cancer cells.

50 ing apoA-I immobilized on nitrocellulose and annexin I in solution with binding detected using anti-a

51 ic mutations in the amino-terminal region of annexin I indicated that Lys-26 and Lys-29 are essential

52 exins and with N-terminal truncated forms of annexin I indicated that the 10-kDa protein bound specif

53 To understand the mechanism by which annexin I induces membrane aggregation, a comprehensive

54 peptide corresponding to amino acids 2-18 of annexin I inhibited the binding of the 10-kDa protein to

55 y assays were performed to verify the apoA-I-annexin I interaction using apoA-I immobilized on nitroc

56 the conformational change of membrane-bound annexin I involving modular rotation of domains (I/IV) f

57 tial proteomics technology, we identify that annexin I is a caspase-dependent engulfment ligand; it i

58 Annexin I is expressed in small sensory neurons of the D

59 ion, we generated truncated mutants of human annexin I lacking various parts of the amino terminus.

60 ty measurements showed that the thickness of annexin I layer bound to the phospholipid monolayer was

61 h immunohistochemical analysis suggests that annexin I may be an essential component for maintenance

62 esults suggest that annexin II, and, likely, annexin I, may be endogenous suppressors of prostate can

63 I(t), since ONOO(-) only slightly influenced annexin I-mediated liposome aggregation.

64 hese results support a hypothetical model of annexin I-mediated membrane aggregation, in which a late

65 To identify amino acids involved in annexin I-mediated membrane aggregation, we generated tr

66 To better understand the mechanism of annexin I-mediated membrane aggregation, we investigated

67 We also show that annexin is membrane-recruited and forms stable supramole

68 significant degree of lateral association of annexin I molecules precedes its membrane aggregation.

69 ds 2-47 of human annexin I (GST-AINT; AINT = annexin I N-terminal).

70 Although the function of annexins is not yet clear, studies have suggested a role

71 , whereas pretreating Jurkat cells with anti-annexin I or removing annexin I with EGTA was inhibitory

72 Monoclonal antibodies (mAbs) against annexins I or II stained a variety of live phagocytes.

73 f apoptotic targets was inhibited by mAbs to annexins I or II, or by pretreatment of macrophages with

74 linded validation study to determine whether annexin I, PGP9.5, and 14-3-3 theta antigens previously

75 Phosphate on [(32)P]annexin I, phosphorylated using both [gamma-(32)P]ATP an

76 loss or a dramatic reduction in the level of annexin I protein expression compared with patient-match

77 Annexin I protein expression was evaluated in patient-ma

78 mechanism(s) and functional consequences of annexin I protein loss in tumor cells are warranted.

79 membrane via the Orai1/TRPC1-mediated Ca(2+)/Annexin I/S100A11 pathway, partially contributing to SOC

80 ling mechanism via the Orai1-mediated Ca(2+)/Annexin I/S100A11 pathway.

81 aluation of membrane aggregation activity of annexin I separately from its membrane binding, revealed

82 uman S100A8/A9 complex and recombinant human annexin I showed carboxylate-dependent binding to immobi

83 Chemical cross-linking of membrane-bound annexin I showed that a significant degree of lateral as

84 cated that both the amino-terminal region of annexin I spanning residues 26-29 and the carboxy-termin

85 The functional hallmark of annexins is the ability to bind to the surface of phosph

86 In the case of annexin I, the new assay is 7-fold more sensitive than t

87 Surface plasmon resonance measurements of annexin I, V, and mutants, which allowed evaluation of m

88 nt study, the spatial expression patterns of annexins I-VI were evaluated in the rat dorsal root gang

89 Immunohistochemical analysis showed that annexin I was expressed diffusely in neoplastic cells in

90 that interact with the N-terminal domain of annexin I, we constructed a fusion protein consisting of

91 POH treatment; p21(Cip1/WAF1), bax, bad, and annexin I were induced; cyclin E and cyclin-dependent ki

92 Jurkat cells with anti-annexin I or removing annexin I with EGTA was inhibitory.